Quality of life and symptom burden among myeloproliferative neoplasm patients

do symptoms impact quality of life?

Blake T. Langlais, Holly Geyer, Robyn Scherber, Ruben A. Mesa, Amylou Dueck

Research output: Contribution to journalArticle

Abstract

Patients with myeloproliferative neoplasms (MPNs) are faced with high disease-related symptom burden and quality of life (QoL) decrements. This analysis assesses the extent to which individual symptoms or summary measures across symptoms impact QoL overall and within MPN subgroups. Four sets of summary measures were constructed assessing symptom prevalence and severity within group-standardized and patient-individualized approaches. Among 1416 international patients with MPNs, mean symptom severity and prevalence were highly correlated (p <.001). Individual symptoms most impacting QoL were inactivity (R2=0.29), fatigue (R2=0.23), and depression (R2=0.23). Multiple symptom severity scores are needed to best predict QoL. Symptom severity at the patient-level is more predictive of QoL than severity at the group-level where a fewer number of symptoms are considered. Having at least one severe symptom and having multiple symptoms of moderate intensity are meaningfully predictive of QoL decrements. Results were highly consistent across disease subgroups.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Quality of Life
Neoplasms
Fatigue

Keywords

  • MPN-SAF
  • Myeloproliferative disorders
  • quality of life
  • symptom burden

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Quality of life and symptom burden among myeloproliferative neoplasm patients : do symptoms impact quality of life? / Langlais, Blake T.; Geyer, Holly; Scherber, Robyn; Mesa, Ruben A.; Dueck, Amylou.

In: Leukemia and Lymphoma, 01.01.2018.

Research output: Contribution to journalArticle

@article{3a0776271f7e41d48d32ee0424d4a236,
title = "Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?",
abstract = "Patients with myeloproliferative neoplasms (MPNs) are faced with high disease-related symptom burden and quality of life (QoL) decrements. This analysis assesses the extent to which individual symptoms or summary measures across symptoms impact QoL overall and within MPN subgroups. Four sets of summary measures were constructed assessing symptom prevalence and severity within group-standardized and patient-individualized approaches. Among 1416 international patients with MPNs, mean symptom severity and prevalence were highly correlated (p <.001). Individual symptoms most impacting QoL were inactivity (R2=0.29), fatigue (R2=0.23), and depression (R2=0.23). Multiple symptom severity scores are needed to best predict QoL. Symptom severity at the patient-level is more predictive of QoL than severity at the group-level where a fewer number of symptoms are considered. Having at least one severe symptom and having multiple symptoms of moderate intensity are meaningfully predictive of QoL decrements. Results were highly consistent across disease subgroups.",
keywords = "MPN-SAF, Myeloproliferative disorders, quality of life, symptom burden",
author = "Langlais, {Blake T.} and Holly Geyer and Robyn Scherber and Mesa, {Ruben A.} and Amylou Dueck",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1480768",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Quality of life and symptom burden among myeloproliferative neoplasm patients

T2 - do symptoms impact quality of life?

AU - Langlais, Blake T.

AU - Geyer, Holly

AU - Scherber, Robyn

AU - Mesa, Ruben A.

AU - Dueck, Amylou

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients with myeloproliferative neoplasms (MPNs) are faced with high disease-related symptom burden and quality of life (QoL) decrements. This analysis assesses the extent to which individual symptoms or summary measures across symptoms impact QoL overall and within MPN subgroups. Four sets of summary measures were constructed assessing symptom prevalence and severity within group-standardized and patient-individualized approaches. Among 1416 international patients with MPNs, mean symptom severity and prevalence were highly correlated (p <.001). Individual symptoms most impacting QoL were inactivity (R2=0.29), fatigue (R2=0.23), and depression (R2=0.23). Multiple symptom severity scores are needed to best predict QoL. Symptom severity at the patient-level is more predictive of QoL than severity at the group-level where a fewer number of symptoms are considered. Having at least one severe symptom and having multiple symptoms of moderate intensity are meaningfully predictive of QoL decrements. Results were highly consistent across disease subgroups.

AB - Patients with myeloproliferative neoplasms (MPNs) are faced with high disease-related symptom burden and quality of life (QoL) decrements. This analysis assesses the extent to which individual symptoms or summary measures across symptoms impact QoL overall and within MPN subgroups. Four sets of summary measures were constructed assessing symptom prevalence and severity within group-standardized and patient-individualized approaches. Among 1416 international patients with MPNs, mean symptom severity and prevalence were highly correlated (p <.001). Individual symptoms most impacting QoL were inactivity (R2=0.29), fatigue (R2=0.23), and depression (R2=0.23). Multiple symptom severity scores are needed to best predict QoL. Symptom severity at the patient-level is more predictive of QoL than severity at the group-level where a fewer number of symptoms are considered. Having at least one severe symptom and having multiple symptoms of moderate intensity are meaningfully predictive of QoL decrements. Results were highly consistent across disease subgroups.

KW - MPN-SAF

KW - Myeloproliferative disorders

KW - quality of life

KW - symptom burden

UR - http://www.scopus.com/inward/record.url?scp=85050559550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050559550&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1480768

DO - 10.1080/10428194.2018.1480768

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -